Редактирование: Aging genes 5-9 (раздел)

==TIGIT==

* {{medline-title
|title=Association of Epigenetic Age and p16INK4a With Markers of T-Cell Composition in a Healthy Cohort.
|date=13.11.2020
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/32361724
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662168
}}
* {{medline-title
|title=Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy.
|date=11-12.2019
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/31578868
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862963
}}
* {{medline-title
|title=Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.
|date=05.2019
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/30768970
|full-text-url=https://sci-hub.do/10.1016/j.jtho.2019.01.024
}}
* {{medline-title
|title=Multivariate Computational Analysis of Gamma Delta T Cell Inhibitory Receptor Signatures Reveals the Divergence of Healthy and ART-Suppressed HIV  Aging.
|date=2018
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/30568654
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290897
}}
* {{medline-title
|title=Characterization of Blimp-1 function in effector regulatory T cells.
|date=07.2018
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/29724515
|full-text-url=https://sci-hub.do/10.1016/j.jaut.2018.04.003
}}
* {{medline-title
|title=T-cell Immunoglobulin and ITIM Domain Contributes to CD8  T-cell Immunosenescence.
|date=04.2018
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/29349889
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847879
}}
* {{medline-title
|title=Long-Lived [[CD4]] IFN-γ  T Cells rather than Short-Lived [[CD4]] IFN-γ IL-10  T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.
|date=15.10.2016
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/27630165
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055201
}}
* {{medline-title
|title=Combinatorial approach to cancer immunotherapy: strength in numbers.
|date=08.2016
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/27256570
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608090
}}